Trial Profile

The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 May 2026 According to a Novo Nordisk media release, data from this study will be presented at the European Association for the Study of the Liver (EASL) Annual Congress 2026 on 27-30 May in Barcelona, Spain.
19 May 2026 Results presented in a Novo Nordisk Media Release.
15 Dec 2025 According to a Novo Nordisk media release, based on results from this trial the Health Canada has issued marketing authorization with conditions [Notice of Compliance with Conditions (NOC/c)] for Wegovy (semaglutide injection) for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com